Position of nuclear medicine modalities in the diagnostic workup of cancer patients: Lung cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 2, 2004, Pages 119-142

  Baum, R P ^a   Hellwig, D ^b   Mezzetti, M ^c  

^a PET Center   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c SAN PAOLO HOSPITAL   (Italy)

Author keywords

Disease recurrence; Fluorodeoxyglucose F18; Lung neoplasms; Neoplasm staging; Pulmonary diseases; Radiotherapy; Tomography, emission computed, single photon; Tomography, emission computed; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; DEPREOTIDE TC 99M; DOXORUBICIN; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SUCCIMER TC 99M; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201; VINCA ALKALOID; DIAGNOSTIC AGENT;

BONE METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DRUG ACCUMULATION; DRUG APPROVAL; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG FUNCTION; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG PERFUSION; LUNG SCINTISCANNING; LUNG SURGERY; LUNG TUMOR; LUNG VENTILATION; MEDIASTINOSCOPY; MEDIASTINUM METASTASIS; MEDICAL LITERATURE; NON INVASIVE MEASUREMENT; NUCLEAR MEDICINE; PALLIATIVE THERAPY; PATIENT CARE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RECURRENT CANCER; REVIEW; SURGICAL RISK; TUMOR VOLUME; BONE TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LYMPH NODE METASTASIS; METASTASIS; PATHOLOGY; SCINTISCANNING;

BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544273775     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe 2000: epidemiology, prevention, and early detection. Lancet Oncology 2003;4:45-53.
2. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2001;12:1049-50.
3. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol 2001;12:1051-2.
4. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours. Berlin: Springer-Verlag; 1999.
5. Thomas M, Baumann M, Deppermann M, Freitag L, Gatzemeier U, Huber R et al. Empfehlungen zur Therapie des Bronchialkarzinoms. Pneumologie 2002;56:113-31.
6. Hoffmann H, Dienemann H. Der pulmonale Rundherd: Prinzipien der Diagnostik. Dt Ärzteblatt 2000;97:A1065-1071.
7. American Thoracic Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respit Crit Care Med 1997;156:320-332.
8. Thomas M, Gatzemeier U, Goerg R, Matthiessen W, Morr H, Schönfeld N et al. Empfehlungen zur Diagnostik des Bronchialkarzinoms. Deutsche Gesellschaft für Pneumologie. Pneumologie 2000;54:361-371.
9. British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001;56: 89-108.
10. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7.
11. Verschakelen JA, Bogaert J, De Wever W. Computed tomography in staging for lung cancer. Eur Respir J Suppl 2002;35: 40s-48s.
12. Deslaurier J. Current surgical treatment of non-small cell lung cancer. Eur Respir J 2002;35:61s-70s.
13. Chiti A, Schreiner EA, Crippa F, Pauwels EK, Bombardieri E. Nuclear medicine procedures in lung cancer. Eur J Nucl Med 1999;26: 533-55.
14. 99mTc Depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-8.
15. Van der Wall H, The evaluation of malignancy: metastatic bone disease. In: Murray IPC, Ell PJ, editors, Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh: Churchill Livingston; 1998.p. 1169-84.
16. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997;15:2996-3018.
17. Oka M, Fukuda M, Sakamoto A, Takatani H, Fukuda M, Soda H et al. The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 1997;17:721-4.
18. 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun 1997;18:1087-97.
19. 99Tcm-sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. Ann Nucl Med 2002; 16:103-8.
20. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med 2002;29:876-81.
21. Kao A, Shiun S, Hsu N, Sun S, Lee C, Lin CC. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and P-glycoprotein or multicrug resistance related protein expression. Ann Oncol 2001;12:1561-6.
22. Hsu W, Yen R, Kao C, Shiun S, Hsu N, Lin C et al. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (>T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein. Oncology 2002;63:173-9.
23. Yamamoto Y, Nishiyama Y, Satoh K, Takashima H, Ohkawa M, Fujita J et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 1998;39:1626-9.
24. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med 2002;32:240-71.
25. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-7.
26. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343: 254-61.
27. Slomka PJ, Dey D, Przetak C, Aladl UE, Baum RP. Automated 3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT. J Nucl Med 2003;44:1156-67.
28. Patton JA, Turkington TG. Coincidence imaging with a dual-head scintillation camera. J Nucl Med 1999;40:432-41.
29. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
30. Albes JM, Lietzenmayer R, Schott U, Schulen E, Wehrmann M, Ziemer G. Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg 1999;47:42-7.
31. Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410-4.
32. Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002;36:297-301.
33. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick M. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997-1002.
34. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997;112:416-22.
35. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52.
36. Duhaylongsod FG, Lowe VJ, Patz EJ, Vaughn AL, Coleman RE, Wolfe W. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9; discussion: 139-40.
37. Graeber GM, Gupta NC. Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117: 719-27.
38. [18F]FDG positron emission tomography (PET). Thorax 1997; 52:438-41.
39. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943-8.
40. Gupta NC, Graeber GM, Rogers JS, Bishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1998;229:286-91.
41. Hagberg RC, Segall GM, Stark P, Burdon TA, Pompili MF. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg 1997;12:92-7.
42. Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN. FDG-PET as a metabolic biopsy tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med 2001;28:1336-40.
43. Halter G, Storck M, Guhlmann A, Frank J, Grosse S, Liewald F. FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions. Thorac Cardiovasc Surg 2000;48:97-101.
44. Hung GU, Shiau YC, Tsai SC, Ho YJ, Kao CH, Yen RF. Differentiation of radiographically indeterminate solitary pulmonary nodules with [F-18]Fluoro-2-deoxyglucose positron emission tomography. Jpn J Clin Oncol 2001;31:51-4.
45. Imdahl A, Jenkner S, Brink I, Nitzsche E, Stoelben E, Moser E et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg 2001;20:324-9.
46. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982-8.
47. Lee J, Aronchick JM, Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review. Chest 2001;120:1791-7.
48. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-6.
49. Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, Hoffman JM, Wolfe WG et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997;202:435-9.
50. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P et al. Prospective investigation of positron emission tomography in lung nodules (PIOPLN). J Clin Oncol 1998;16:1075-84.
51. Menda Y, Bushnell DL, Madsen MT, McLaughlin K, Kahn D, Kernstine KH. Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. Nucl Med Commun 2001;22:1077-81.
52. Pitman AG, Hicks RJ, Binns DS, Ware RE, Kalff V, McKenzie AF et al. Performance of sodium iodide based (18)F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses. Br J Radiol 2002;75:114-21.
53. Präuer HW, Weber WA, Römer W, Treumann T, Ziegler SI, Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998;85: 1506-11.
54. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.
55. [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994;58:698-703.
56. 18F-fluorodeoxyglucose positron emission tomography using a partial-ring tomograph without attenuation correction to differentiate benign and malignant pulmonary nodules. Can Assoc Radiol J 2001; 52:259-65.
57. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285: 914-24.
58. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2001]. Pneumologie 2001;55:367-77.
59. Hübner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S et al. Differentiating benign from malignant lung lesions using quantitative parameters of FDG PET images. Clin Nucl Med 1996;21:941-9.
60. Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000;25:273-8.
61. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point F-18 FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5.
62. 18F-FDE PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-7.
63. Wu J, Baum RP. The 18F-FDG uptake in non small cell lung carcinoma correlates with the DNA-grading of malignancy. Chin J Nucl Med 2002;22:116-7.
64. Baum RP, Bonnet RB, Presselt N, Leonhardi J. Positronen-Emissions-Tomographie (PET) mit F-18-FDG in der Diagnostik des Bronchi-alkirzinoms und zur Dignitätsklärung von pulmonalen Raumforderungen. Nuklearmediziner 2001;24:9-23.
65. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:1016-20.
66. Hellwig D, Gröschel A, Rentz K, Sybrecht GW, Kirsch CM, Ukena D. Aussagekraft der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) beim Bronchioloalveolarzell-Karzinom (BAC). Pneumologie 2001;55:363-6.
67. Yap S, Schiepers C, Fishbein C, Phelps E, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002;29:1166-73.
68. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369-73.
69. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Americ J Roentgenol 2000;174:1005-8.
70. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8.
71. Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993;34:355-9.
72. Arita T, Kuramitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995;50:1267-9.
73. Arita T, Matsumoto T, Kuramitsu T, Kawamura M, Matsunaga N, Sugi K et al. Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen. Chest 1996; 110:1004-8.
74. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705-13.
75. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl R. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - metaanalytic comparison of PET and CT. Radiology 1999;213:530-6.
76. 18F fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999;16(Suppl 1):S25-30.
77. Bury T, Dowlati A, Paulus P, Corhay JL, Hustinx R, Ghaye B et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-34.
78. Chin RJ, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090-6.
79. Farrell MA, McAdams HP, Herndon JE, Patz EF. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 2000;215:886-90.
80. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucosein evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000;117:773-8.
81. Gupta NC, Tamin WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer. Chest 2001;120:521-7.
82. Higashi K, Nishikawa T, Seki H, Oguchi M, Nambu Y, Ueda Y et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9-15.
83. Kernstine KH, Stanford W, Mullan BF, Rossi NP, Thompson BH, Bushnell DL et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1022-8.
84. Kernstine KH, Mclaughlin KA, Menda Y, Rossi NP, Kahn DJ, Bushnell DL et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable non-small cell lung cancer? Ann Thorac Surg 2002;73:394-401; discussion 402.
85. Liewald F, Grosse S, Storck M, Guhlmann A, Halter G, Reske S et al. How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer? Thorac Cardiovasc Surg 2000;48:93-6.
86. Magnani P, Carretta A, Rizzo G, Fazio F, Vanzulli A, Lucignani G et al. FDG-PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg (Torino) 1999;40:741-8.
87. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE et al. Staging non-small cell lung cancer with wholebody PET. Radiology 1999;212:803-9.
88. 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617-21.
89. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001;20:468-74; discussion 474-5.
90. Roberts PF, Follette DM, von Haag D, Park JA, Valk PE, Pounds TR et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000;70: 1154-9; discussion 1159-60.
91. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland J. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-8.
92. Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-6.
93. Tatsumi M, Yutani K, Watanabe Y, Miyoshi S, Tomiyama N, Johkoh T et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999;40:566-73.
94. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-81; discussion 1581-2.
95. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-9.
96. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-24.
97. Vesselle H, Pugsley JM, Vallieres E, Wood DE. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;124:511-9.
98. Von Haag DW, Follette DM, Roberts PF, Shelton D, Segel LD, Taylor TM. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res 2002;103:160-4.
99. 18F-Fluorodeoxyglukose in der Diagnostik des nicht kleinzelligen Bronchialkarzinoms: evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen. Nuklearmedizin 2003;42:135-44.
100. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167-77.
101. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
102. Collins BT, Lowe VJ, Dunphy F. Initial evaluation of pulmonary abnormalities: CT-guided fine-needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography correlation. Diagn Cytopathol 2000;22:92-6.
103. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93.
104. Saunders CA, Dussek JE, O'Doherty MJ, Maisey M. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7.
105. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert H. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66: 886-92.
106. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7.
107. 99mTc MDP bone scan to detect bone metastases. Anticancer Res 2000;20:2189-92.
108. Boland GW, Goldberg MA, Lee MJ, Mayo Smith WW, Dixon J, McNicholas MM et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4.
109. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-60.
110. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-9.
111. Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N et al. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J 1999;14:1376-80.
112. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP et al. The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001; 42:1605-13.
113. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-93.
114. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191: 379-82.
115. Ukena D, Hellwig D, Palm I, Rentz K, Leutz M, Hellwig AP et al. Stellenwert der Positronen-Emissions-Tomographie mit 18-Fluor-Desoxyglukose (FDG-PET) in der Rezidivdiagnostik des Bronchialkarzinoms. Pneumologie 2000;54:49-53.
116. 18FDG-PET and CT after combined radiochemotherapy for advanced non-small-cell lung cancer: a study in 15 patients. Front Radiat Ther Oncol 2002;37:26-33.
117. Nestle U, Hellwig D, Schmidt S, Licht N, Walter K, Ukena D et al. 2-Deoxy-2-[18-F]-fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imag Biol 2002;4:1-7
118. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-8.
119. MacManus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-95.
120. Schmücking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation therapy planning. Recent Results in Cancer Res 2003;162:195-202.
121. Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-50.
122. Giraud P, Elles S, Helfre S, De Rycke Y, Servois V, Carette MF et al. Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. Radiother Oncol 2002;62:27-36.
123. Hebert ME, Lowe VJ, Hoffmann JM. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-21.
124. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44: 593-7.
125. Munley MT, Marks LB, Scarfone C, Sibley GS, Patz EF Jr, Turkington TG et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 1999;23:105-14.
126. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study Group. Eur J Cancer 1999;35:1773-82.
127. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001;45:257-68.
128. Hör G, Adams S, Baum RP, Hertel A, Adamietz I, Böttcher HD et al. Impact of SPECT and PET in Diagnostic Oncology. Diagn Oncol 1997;4.
129. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C et al. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
130. Vansteenkiste JF. Imaging in lung cancer: positron emission tomography scan. Eur Respir J 2002;35:49s-60s.
131. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224-39.
132. Baum RP, Griesinger F, Niesen A. Correlation of FDG-PET measurements with morphometric tumor response after induction chemotherapy and adjuvant radiotherapy in stage III non-small cell lung Cancer (NSCLC). In: 25th International Symposium Radioactive Isotopes in Clinical Medicine and Research. Abstractbook. 2002 January 8-11, Bad Gastein, Austria.
133. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-87.
134. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73:259-64; discussion 264-6.
135. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998;66:1876-83; discussion 1883-5.
136. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
137. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428-36.
138. Dietlein M, Moka D, Weber K, Theissen P, Schicha H. [Cost-effectiveness of PET for the management of lung tumors: comparison to economic data]. Nuklearmedizin 2001;40:122-8.
139. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000;27:1441-56.
140. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27:1598-609.
141. Herder GJ, Verboom P, Smit EF, van Velthoven PC, van den Bergh JH, Colder CD et al. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax 2002;57:11-4.
142. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[18F]-fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest 2000;117:346-53.
143. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med 2002;16:263-71.
144. Miles KA. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Australas Radiol 2001;45:9-18.
145. Chin R, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas Case L et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002;37:1-6.
146. Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483-8.
147. Hauber HP, Bohuslavizki KH, Lund CH, Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001;119:950-4.
148. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]-FDG-PET imaging in small cell lung cancer. Eur J Nucl Med 2003;30:78-84.
149. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med. 2002;32:272-5.
150. Reske S, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET